Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy
Pre-clinicalRecruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia Associated With Type II Diabetes Mellitus
Conditions
Dyslipidemia Associated With Type II Diabetes Mellitus
Trial Timeline
Mar 9, 2026 → Dec 31, 2029
NCT ID
NCT07359105About Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy
Moderate-intensity statin monotherapy + Ezetimibe or ezetimibe-statin combination therapy is a pre-clinical stage product being developed by Yuhan for Dyslipidemia Associated With Type II Diabetes Mellitus. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07359105. Target conditions include Dyslipidemia Associated With Type II Diabetes Mellitus.
What happened to similar drugs?
15 of 20 similar drugs in Dyslipidemia Associated With Type II Diabetes Mellitus were approved
Approved (15) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07359105 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Dyslipidemia Associated With Type II Diabetes Mellitus